Could get interesting, exect a partnership soon, ...
Abstract #: 2145
Title: "PSMA-specific anti-tumor activity of the targeted-tubulysin conjugate, EC1169"
When: Monday, April 8, 1 p.m. -- 5 p.m. EDT
Session ID: Novel Targeted Therapies 1
Location: Hall A-C, Poster Section 40
Abstract #: 4499
Title: "Total synthesis of tubulysins: A new chemical reaction leads to analogues with enhanced cytotoxicity"
When: Tuesday, April 9, 1 p.m. -- 5 p.m. EDT
Session ID: Genome and Microtubule Integrity
Location: Hall A-C, Poster Section 42
Abstract #: 5623
Title: "Extracellular thiols and system xc play a significant role in non-targeted in vitro activity of a folate-tubulysin B conjugate"
When: Wednesday, April 10, 8 a.m. -- noon EDT
Session ID: Novel Delivery Technologies
Location: Hall A-C, Poster Section 41
Abstract #: 5502
Title: "Vintafolide: a first-in-class small molecule drug conjugate targeting folate receptor positive tumor
Partner for EC1169 may pay more upfront than Merck did for Vintafolide:
"human xenografts with EC1169 led to complete remissions in 5/7 mice, and cures (i.e. tumor free 90 days post implantation) in 2/7 mice. Furthermore, this activity occurred in the absence of weight loss or major organ tissue degeneration."
If/When Endocyte announces a partner for a second small molecule drug conjugate the sky is the limit. I'm guessing Merck is watching closely and comparing data on new drugs to their Vintafolide. Think this has something to do with the huge price surge? Haven't sold a share as I suspect good news in the next few months on Europe and/or a second licensing to be announced.